The Life Sciences team advised Braveheart Bio, Inc. (Nasdaq: BRVE) on closing its upsized initial public offering of an aggregate of 24,437,500 shares of its common stock at an initial public offering price of $18.00 per share, including the full exercise by the underwriters of their option to purchase 3,187,500 additional shares. All shares of common stock were offered by Braveheart Bio. The shares began trading on the Nasdaq Global Market on August 6, 2026, under the ticker symbol “BRVE”. The gross proceeds from the initial public offering were $439.9 million.
Braveheart Bio is a clinical-stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases. Braveheart Bio’s lead product candidate, BHB-1893, is a next-generation oral small-molecule cardiac myosin inhibitor (CMI) being developed for the treatment of obstructive HCM (oHCM) and non-obstructive HCM (nHCM). Braveheart Bio’s goal is to improve the treatment options for these patients by enhancing speed of onset, depth of gradient response, systolic safety, reversibility, and reducing prescribing complexity.
The Goodwin team was led by Gaby Morales-Rivera, Kingsley Taft, Alicia Tschirhart, Swetha Gopalakrishnan, Bonnee Nie, Grace Wirth, Chris Jones, Dasol Lee, Julie Tibbets, Krupa Zachariah, Matthew Wetzel, Jennifer Fay, Nina Ngo, David Chen, Jennifer Ford, and Maggie Wong.
For more information on the deal, please read the press release.